文献速递免疫规划传染病防控与疫情报告

CHO表达的重组SARS-CoV-2刺突S1-Fc融合蛋白在非人灵长类中诱导高水平中和反应

Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
PubMed 文献 · Vaccine · 2020-06-24

本研究在 mice、兔和猴中评估CHO表达的重组SARS-CoV-2 S1-Fc融合蛋白作为COVID-19疫苗候选物的免疫原性。结果显示该蛋白免疫原性极强,第7天即可观察到强抗体滴度,兔在第14天假病毒中和试验中显示强病毒中和活性;两只猴在不足20天三次注射后,活SARS-CoV-2感染试验中的中和滴度高于一名康复患者。

要点

  • S1-Fc融合蛋白免疫原性极强,第7天即可测得强抗体滴度。
  • 兔第14天假病毒中和试验显示强病毒中和活性。
  • 猴三次注射不足20天,活病毒中和滴度高于康复患者。

核心结论

  • CHO表达的重组SARS-CoV-2 S1-Fc融合蛋白在 mice、兔和猴中显示强免疫原性,并诱导高水平中和反应,可能是COVID-19疫苗开发的强候选物。

研究设计与样本

  • 在 mice、兔和猴中评估CHO表达的重组SARS-CoV-2 S1-Fc融合蛋白的免疫原性。

主要发现

  • 第7天通过抗体滴度观察到强免疫原性。
  • 兔在第14天假病毒中和试验中显示强病毒中和活性。
  • 两只猴在不足20天三次注射后,活SARS-CoV-2感染试验中的中和滴度高于一名康复COVID-19患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. Most importantly, in <20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ren W, Sun H, Gao GF, et al. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. Vaccine. 2020. PMID: 32651113. doi:10.1016/j.vaccine.2020.06.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。